Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...
Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...
Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...
Among low-risk patients with acute MI who underwent early complete revascularization and received one month of dual antiplatelet therapy (DAPT), P2Y12 inhibitor monotherapy was noninferior to ...
Among oral P2Y12 inhibitors, prasugrel appears to have the best balance between risks and benefits in patients who have undergone PCI, according to a new meta-analysis. Compared with clopidogrel, ...
One month of dual antithrombotic therapy may be enough for patients with atrial fibrillation (AF) and stable coronary artery disease undergoing percutaneous coronary intervention (PCI), according to a ...
A major international study has found that heart patients, particularly seniors, may benefit more from newer blood-thinning medications called P2Y12 inhibitors than traditional aspirin therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results